Seeking Alpha
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

Merck's Late-Stage Pipeline Should Pay Dividends

It's easy to get caught up on the topic of patent cliff, but we think a forward-looking assessment within a pharma's pipeline is a more constructive conversation. Though Merck (MRK) has lost exclusivity on a number of key drugs in the recent past, its late-stage pipeline is budding with new prospects. The company has more than a dozen promising Phase III programs, and any one of them has the potential to drive material improvement in the back half of this decade. The market, however, is paying attention, and at the moment, is not offering Merck's shares up at a bargain. This is typical for strong firms with solid prospects. They often don't go on sale.

Merck's Investment Considerations

Investment Highlights

• Merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, and biologic therapies. Januvia/Janumet for type 2 diabetes and Zetia/Vytorin for cholesterol… Read More …